More on Cubist Pharmaceuticals (CBST): Q2 comes in mixed, missing on the bottom line but beating...

More on Cubist Pharmaceuticals (CBST): Q2 comes in mixed, missing on the bottom line but beating on top line revenue. Net earnings fell 65% as the biopharmaceutical company was hit by higher costs that more than offset 12% Y/Y revenue growth. U.S. Cubicin sales jumped 14% to $227.1M, while Entereg sales climbed 28% to $12.4M. R&D expenses also surged however, rising 71% to $115.2M. Shares +1.2% AH.